JP2011516410A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011516410A5 JP2011516410A5 JP2010548040A JP2010548040A JP2011516410A5 JP 2011516410 A5 JP2011516410 A5 JP 2011516410A5 JP 2010548040 A JP2010548040 A JP 2010548040A JP 2010548040 A JP2010548040 A JP 2010548040A JP 2011516410 A5 JP2011516410 A5 JP 2011516410A5
- Authority
- JP
- Japan
- Prior art keywords
- fibrosis
- modified
- compound according
- compound
- sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 206010016654 Fibrosis Diseases 0.000 claims 8
- 230000004761 fibrosis Effects 0.000 claims 8
- 108091034117 Oligonucleotide Proteins 0.000 claims 6
- 239000002777 nucleoside Substances 0.000 claims 6
- 125000003835 nucleoside group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 210000002950 fibroblast Anatomy 0.000 claims 3
- 206010013012 Dilatation ventricular Diseases 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 108091062762 miR-21 stem-loop Proteins 0.000 claims 2
- 108091041631 miR-21-1 stem-loop Proteins 0.000 claims 2
- 108091044442 miR-21-2 stem-loop Proteins 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 238000004904 shortening Methods 0.000 claims 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 206010019668 Hepatic fibrosis Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010050207 Skin fibrosis Diseases 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000893 fibroproliferative effect Effects 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000004217 heart function Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3183508P | 2008-02-27 | 2008-02-27 | |
| US61/031,835 | 2008-02-27 | ||
| EP08003570.2 | 2008-02-27 | ||
| EP20080003570 EP2096171A1 (en) | 2008-02-27 | 2008-02-27 | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
| US3334008P | 2008-03-03 | 2008-03-03 | |
| US61/033,340 | 2008-03-03 | ||
| EPPCT/EP2009/051986 | 2009-02-19 | ||
| PCT/EP2009/051986 WO2009106477A1 (en) | 2008-02-27 | 2009-02-19 | Microrna (mirna) and down-stream targets for diagnostic and therapeutic purposes |
| PCT/EP2009/001590 WO2009106367A1 (en) | 2008-02-27 | 2009-02-26 | Microrna (mirna) and downstream targets for diagnostic and therapeutic purposes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014246185A Division JP2015107971A (ja) | 2008-02-27 | 2014-12-04 | 診断および治療のためのミクロＲＮＡ（ｍｉＲＮＡ）および下流標的 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011516410A JP2011516410A (ja) | 2011-05-26 |
| JP2011516410A5 true JP2011516410A5 (enExample) | 2013-01-17 |
| JP6033527B2 JP6033527B2 (ja) | 2016-11-30 |
Family
ID=39639202
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010548040A Active JP6033527B2 (ja) | 2008-02-27 | 2009-02-26 | 診断および治療のためのミクロＲＮＡ（ｍｉＲＮＡ）および下流標的 |
| JP2014246185A Pending JP2015107971A (ja) | 2008-02-27 | 2014-12-04 | 診断および治療のためのミクロＲＮＡ（ｍｉＲＮＡ）および下流標的 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014246185A Pending JP2015107971A (ja) | 2008-02-27 | 2014-12-04 | 診断および治療のためのミクロＲＮＡ（ｍｉＲＮＡ）および下流標的 |
Country Status (23)
| Country | Link |
|---|---|
| US (10) | US8236777B2 (enExample) |
| EP (3) | EP2096171A1 (enExample) |
| JP (2) | JP6033527B2 (enExample) |
| KR (1) | KR101697482B1 (enExample) |
| CN (1) | CN102027113B (enExample) |
| AU (1) | AU2009218704C1 (enExample) |
| BR (1) | BRPI0907565B1 (enExample) |
| CA (2) | CA2716643C (enExample) |
| CY (1) | CY1114426T1 (enExample) |
| DK (1) | DK2260101T3 (enExample) |
| EA (1) | EA020335B1 (enExample) |
| ES (1) | ES2436885T3 (enExample) |
| HR (1) | HRP20130766T1 (enExample) |
| IL (1) | IL207704A (enExample) |
| ME (1) | ME01600B (enExample) |
| MX (2) | MX2010009346A (enExample) |
| MY (1) | MY159454A (enExample) |
| NZ (1) | NZ588185A (enExample) |
| PL (1) | PL2260101T3 (enExample) |
| PT (1) | PT2260101E (enExample) |
| SI (1) | SI2260101T1 (enExample) |
| UA (1) | UA100727C2 (enExample) |
| WO (2) | WO2009106477A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2534302T3 (es) | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| EP2096171A1 (en) | 2008-02-27 | 2009-09-02 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
| US20110190372A1 (en) * | 2009-08-07 | 2011-08-04 | New York University | Compositions and methods for treating inflammatory disorders |
| CN102038959B (zh) * | 2009-10-26 | 2012-12-19 | 中国科学院上海生命科学研究院 | let-7/miR-98家族在制备治疗FAS基因相关疾病的药物中的应用 |
| WO2011126842A2 (en) * | 2010-03-30 | 2011-10-13 | Regulus Therapeutics Inc. | Targeting micrornas for the treatment of cardiac disorders |
| US20130150256A1 (en) | 2010-06-11 | 2013-06-13 | Jane Synnergren | Novel micrornas for the detection and isolation of human embryonic stem cell-derived cardiac cell types |
| WO2012012716A2 (en) * | 2010-07-23 | 2012-01-26 | Regulus Therapeutics, Inc. | Targeting micrornas for the treatment of fibrosis |
| WO2012083005A2 (en) * | 2010-12-15 | 2012-06-21 | Miragen Therapeutics | Microrna inhibitors comprising locked nucleotides |
| CN103620035B (zh) * | 2011-04-25 | 2021-04-23 | 赛诺菲 | 用于调节mir-21活性的微rna化合物以及方法 |
| CN104011208B (zh) * | 2011-09-06 | 2020-04-10 | 马普科技促进协会 | 作为治疗靶的miRNA-212/132家族 |
| KR20140091688A (ko) | 2011-10-06 | 2014-07-22 | 미라젠 세러퓨틱스 인코포레이티드 | 마이크로rna 조절에 의한 전신 에너지 항상성의 제어 |
| EP2592145A1 (en) * | 2011-11-11 | 2013-05-15 | Medizinische Hochschule Hannover | Medicament for the treatment of cardiac disease |
| MX2014006130A (es) * | 2011-11-22 | 2015-04-13 | Intermune Inc | Metodos de diagnostico y tratamiento de la fibrosis pulmonar idiopatica. |
| CA2859430A1 (en) * | 2011-12-13 | 2013-06-20 | Ohio State Innovation Foundation | Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis |
| WO2013153082A1 (en) * | 2012-04-10 | 2013-10-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of nonalcoholic steatohepatitis |
| BR112014026639A8 (pt) * | 2012-04-25 | 2018-01-16 | Regulus Therapeutics Inc | compostos , métodos de inibição da atividade de mir-21 , método para diminuir a expressão de colágeno , método para tratar , prevenir ou atrasar o início de uma doença , método de tratamento de um distúrbio fibroproliferativo e usos de um composto. |
| CA2876180C (en) | 2012-06-21 | 2019-11-19 | MiRagen Therapeutics, Inc. | Oligonucleotide-based inhibitors comprising locked nucleic acid motif |
| CA2782942C (en) * | 2012-07-12 | 2019-08-27 | Canadian Blood Services | Method for inducing immune tolerance using polymer-modified antigenic leukocytes |
| UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| WO2015003240A1 (en) | 2013-07-12 | 2015-01-15 | Canadian Blood Services | Acellular pro-inflammatory compositions, process for making same and methods of using same |
| EP3060664B1 (en) | 2013-10-25 | 2021-07-07 | Sanofi | Microrna compounds and methods for modulating mir-21 activity |
| EP3079727A1 (en) * | 2013-12-12 | 2016-10-19 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for the prevention and treatment of diabetic cardiomyopathy using mir-424/322 |
| WO2016004538A1 (en) | 2014-07-10 | 2016-01-14 | Canadian Blood Services | Combination therapy of a cellular pro-tolerogenic and pro-inflammatory preparations for modulating the immune system |
| EP3201213B1 (en) * | 2014-09-08 | 2021-06-02 | Viridian Therapeutics, Inc. | Mir-29 mimics and uses thereof |
| SG11201705907XA (en) | 2015-01-20 | 2017-08-30 | Miragen Therapeutics Inc | Mir-92 inhibitors and uses thereof |
| CN106924757B (zh) * | 2015-12-31 | 2020-07-24 | 中国科学院遗传与发育生物学研究所 | miR-449c-5p及其拟似物在制备治疗和预防心脏瓣膜疾病产品中的应用 |
| CN107034216A (zh) * | 2016-02-04 | 2017-08-11 | 中国科学技术大学 | miRancer分子的设计与应用 |
| KR101835018B1 (ko) | 2016-03-03 | 2018-03-06 | 고려대학교 산학협력단 | 엑소좀 또는 엑소좀 유래 리보핵산을 포함하는 간섬유증 예방 또는 치료용 조성물 |
| US11236337B2 (en) | 2016-11-01 | 2022-02-01 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
| US11667916B2 (en) | 2017-09-08 | 2023-06-06 | Korea University Research And Business Foundation | Composition for preventing or treating liver fibrosis, containing exosome or exosome-derived ribonucleic acid |
| CN107858419A (zh) * | 2017-11-10 | 2018-03-30 | 青岛大学 | miRNA的应用、应用其的产品及检测方法 |
| US20210189398A1 (en) | 2018-05-25 | 2021-06-24 | Bioneer Corporation | Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same |
| CN109498642A (zh) * | 2018-12-21 | 2019-03-22 | 复旦大学附属中山医院 | 一种柯萨奇b3病毒感染导致的心脏微血管病变的靶向治疗药物 |
| KR20230008741A (ko) | 2020-04-09 | 2023-01-16 | 테크니쉐 우니베르지테트 뮌헨 | 폐 섬유증 치료를 위한 miR-21 억제제의 대식세포로의 표적 전달 |
| WO2021262919A2 (en) | 2020-06-26 | 2021-12-30 | The Research Foundation For The State University Of New York | 5-halouracil-modified micrornas and their use in the treatment of cancer |
| US20230302139A1 (en) * | 2020-07-31 | 2023-09-28 | University Of Florida Research Foundation, Incorporated | Targeted rna degradation allows precision repurposing of protein-targeted small molecule medicines to rna |
| WO2022184888A2 (en) * | 2021-03-05 | 2022-09-09 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for use in the treatment of corneal dystrophies |
| KR102549208B1 (ko) * | 2021-04-08 | 2023-06-30 | 연세대학교 산학협력단 | 심혈관 질환과 관련된 LncRNA 및 이의 용도 |
| CN118667869B (zh) * | 2024-07-10 | 2025-06-27 | 中国水稻研究所 | 水稻氮素利用基因nu4在调控水稻生长中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1768139A (zh) * | 2003-02-10 | 2006-05-03 | 独立行政法人产业技术总合研究所 | 通过dna干扰调控基因的表达 |
| EP1606406B2 (en) * | 2003-03-21 | 2013-11-27 | Santaris Pharma A/S | SHORT INTERFERING RNA (siRNA) ANALOGUES |
| CN1905876B (zh) * | 2003-11-17 | 2010-06-09 | 诺瓦提斯公司 | 二肽基肽酶iv抑制剂的用途 |
| CA2566519C (en) | 2004-05-14 | 2020-04-21 | Rosetta Genomics Ltd. | Micrornas and uses thereof |
| US20060142193A1 (en) * | 2004-11-09 | 2006-06-29 | Baylor College Of Medicine | Selective inhibition of rock1 in cardiac therapy |
| US20070213292A1 (en) * | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| CA3024953A1 (en) * | 2006-04-03 | 2007-10-11 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| EP2476762B1 (de) | 2006-10-09 | 2014-01-08 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) zur Diagnose und Therapie von Herzerkrankungen |
| AU2007333107A1 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-21 regulated genes and pathways as targets for therapeutic intervention |
| WO2009058818A2 (en) | 2007-10-29 | 2009-05-07 | The Board Of Regents Of The University Of Texas System | Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling |
| EP2096171A1 (en) | 2008-02-27 | 2009-09-02 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
-
2008
- 2008-02-27 EP EP20080003570 patent/EP2096171A1/en not_active Withdrawn
-
2009
- 2009-02-19 WO PCT/EP2009/051986 patent/WO2009106477A1/en not_active Ceased
- 2009-02-26 PL PL09714079T patent/PL2260101T3/pl unknown
- 2009-02-26 AU AU2009218704A patent/AU2009218704C1/en not_active Ceased
- 2009-02-26 PT PT97140792T patent/PT2260101E/pt unknown
- 2009-02-26 ME MEP-2013-93A patent/ME01600B/me unknown
- 2009-02-26 CA CA2716643A patent/CA2716643C/en active Active
- 2009-02-26 US US12/919,592 patent/US8236777B2/en active Active
- 2009-02-26 UA UAA201011410A patent/UA100727C2/ru unknown
- 2009-02-26 WO PCT/EP2009/001590 patent/WO2009106367A1/en not_active Ceased
- 2009-02-26 JP JP2010548040A patent/JP6033527B2/ja active Active
- 2009-02-26 MY MYPI2010004041A patent/MY159454A/en unknown
- 2009-02-26 HR HRP20130766AT patent/HRP20130766T1/hr unknown
- 2009-02-26 NZ NZ588185A patent/NZ588185A/xx not_active IP Right Cessation
- 2009-02-26 KR KR1020107021182A patent/KR101697482B1/ko not_active Expired - Fee Related
- 2009-02-26 EA EA201070992A patent/EA020335B1/ru unknown
- 2009-02-26 DK DK09714079.2T patent/DK2260101T3/da active
- 2009-02-26 BR BRPI0907565-8A patent/BRPI0907565B1/pt not_active IP Right Cessation
- 2009-02-26 EP EP09714079.2A patent/EP2260101B1/en active Active
- 2009-02-26 EP EP20130160931 patent/EP2628800A1/en not_active Withdrawn
- 2009-02-26 MX MX2010009346A patent/MX2010009346A/es active IP Right Grant
- 2009-02-26 CN CN200980115916.9A patent/CN102027113B/zh active Active
- 2009-02-26 ES ES09714079.2T patent/ES2436885T3/es active Active
- 2009-02-26 CA CA3123067A patent/CA3123067A1/en not_active Abandoned
- 2009-02-26 MX MX2011012838A patent/MX336299B/es unknown
- 2009-02-26 SI SI200930690T patent/SI2260101T1/sl unknown
-
2010
- 2010-08-19 IL IL207704A patent/IL207704A/en active IP Right Grant
-
2012
- 2012-06-28 US US13/535,652 patent/US8592389B2/en not_active Expired - Fee Related
-
2013
- 2013-08-13 CY CY20131100690T patent/CY1114426T1/el unknown
- 2013-10-23 US US14/061,350 patent/US9220722B2/en active Active
-
2014
- 2014-12-04 JP JP2014246185A patent/JP2015107971A/ja active Pending
-
2015
- 2015-11-20 US US14/947,291 patent/US9663788B2/en active Active
-
2017
- 2017-04-19 US US15/491,633 patent/US10028974B2/en active Active
-
2018
- 2018-06-22 US US16/015,495 patent/US10434117B2/en active Active
-
2019
- 2019-08-16 US US16/542,985 patent/US20200069720A1/en not_active Abandoned
-
2020
- 2020-09-01 US US17/008,782 patent/US20210113603A1/en not_active Abandoned
-
2022
- 2022-06-22 US US17/846,518 patent/US20230028937A1/en not_active Abandoned
-
2023
- 2023-11-21 US US18/515,531 patent/US20240189339A1/en not_active Abandoned